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The COVID-19 pandemic will impact on how care for chronic 
conditions is delivered. We use epilepsy to exemplify how 
care for patients will be affected, and suggest ways in which 
healthcare systems can respond to deliver the most effective 
care. Where face-to-face outpatient appointments have 
been cancelled, telemedicine can facilitate remote clinical 
consultations for new and follow-up epilepsy clinic patients while 
reducing the risk of infection to both patients and healthcare 
staff. First-seizure patients will need investigation pathways 
rationalised, while those with chronic epilepsy will need to have 
reliable alternative avenues to access clinical advice. At the same 
time, neurologists should support emergency departments and 
acute medical units, advising on appropriate management of 
seizures and other acute neurological presentations. Ultimately, 
the revolution in our clinical practice is unlikely to cease after 
this pandemic, with reconfiguration of services likely to bring 
improvements in efficiency and convenience, and a reduced 
environmental impact.




Coronavirus disease 2019 (COVID-19) is a rapidly spreading 
infectious disease caused by the novel human coronavirus, severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2).1 At present 
we do not know, but it seems unlikely, that having epilepsy puts 
people at greater risk of COVID-19; however, epilepsy is associated 
with a number of comorbidities that do increase risk. Epilepsy is also 
associated with health inequalities, which worsen during pandemics 
and further diminish contact with services when help is needed.2,3
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The COVID-19 pandemic is having, and will continue to have, 
a significant impact on how epilepsy care is delivered. The major 
challenge will be determining how epilepsy services respond most 
appropriately, ensuring safe pathways for those with likely first 
seizures, as well as access for those with an established epilepsy 
diagnosis. This is at a time when neurologists and specialist nurses 
are being redeployed to areas of significant clinical need, including 
intensive care and acute medical units, supporting their colleagues 
on the frontline. For many, this is an unfamiliar role requiring 
refresher courses and retraining.
Redeployment has inevitably led to less time to dedicate to 
epilepsy care, and the ongoing management of many other chronic 
diseases. However, despite the unprecedented challenges that 
healthcare systems are facing, we still have a duty of care to people 
with epilepsy (PWE), and to those presenting with first seizures. 
Having robust plans and protocols for continued effective epilepsy 
care is essential to minimise avoidable presentations to both 
primary and secondary care, and to minimise risk to those unable or 
unwilling to seek help.  
Telemedicine
To respond to the COVID-19 pandemic, changes to services have 
been made at unprecedented speed, including the widespread 
implementation of telemedicine.4 Governments have introduced 
various measures to encourage social distancing and discourage 
non-essential travel to limit spread of the disease. This has led 
to a move away from the traditional congregation of patients in 
epilepsy outpatient clinic waiting areas, in order to reduce infection 
risk to both NHS staff and patients. 
Telephone consultations have been shown to be both effective 
and efficient in providing a remote epilepsy service, although 
specialised digital audiovisual technology is being rapidly deployed 
for both new and follow-up epilepsy clinic patients.5,6 While there are 
limitations that come with telemedicine, such as reduced ability to 
perform physical examination, in epilepsy care physical examination 
is rarely necessary, particularly for chronic disease management, 
and epilepsy would seem an ideal condition for using telemedicine.7 
The changed human interaction may, however, diminish the ability 
to pick up non-verbal and some verbal cues, which are particularly 
important in functional presentations. This may result in greater 
diagnostic error, including the misdiagnosis of dissociative seizures 
as epileptic seizures. This can be mitigated by simultaneously 
seeking the account of an eyewitness as part of the remote 
consultation and having a low threshold to revisit the diagnosis, 
depending on further events or response to treatment. If performed 
successfully, remote consultation in epilepsy has the potential  
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to serve as an exemplar, leading to implementation in other  
medical specialties.
First seizures
A first seizure is a common presentation, and a swift assessment 
is crucial to identify those with serious underlying pathology or at 
higher risk of recurrence, in order to minimise risk and provide advice 
about driving and employment. This is recognised in National 
Institute for Health and Care Excellence (NICE) guidance, which 
recommends a 2-week urgent referral.8 In addition, many patients 
are put on first-seizure pathways despite having had syncope, and a 
rapid assessment avoids unnecessary delay in a return to driving, as 
well as onward referral to cardiology for those who need it. 
Most first-seizure patients can be assessed by telemedicine, 
followed by a face-to-face appointment if absolutely necessary. 
Decisions should then be made about investigations. First-seizure 
patients should have brain imaging, but routine magnetic resonance 
imaging (MRI) scanning is currently reduced or cancelled in some 
units due to the challenges of deep cleaning MRI facilities. Most 
first-seizure patients will have a computed tomography (CT) scan, 
often unenhanced, in the emergency department (ED), which will 
rule out most serious pathologies. Until the COVID-19 pandemic 
is over, MRI should be reserved for those patients with a high 
probability of a serious underlying lesion such as a tumour – 
mainly those with rapid onset of frequent seizures and those with 
neurological deficits or signs. For patients who have not had imaging 
in the ED or have come from primary care, an enhanced CT scan 
should be booked if MRI is unavailable. 
The vast majority of patients presenting to acute care settings 
with a possible seizure will have already had an electrocardiogram 
(ECG) performed. If an ECG has not been performed, a 12-lead 
tracing should be requested, with priority given to those with a 
history suggesting syncope rather than seizure, those with a family 
history of sudden cardiac death and those taking drugs associated 
with QT prolongation.9 Regarding electroencephalogram (EEG), 
in adult care the great majority of first-seizure and new epilepsy 
patients can be managed in the first instance without an EEG, as 
treatment to prevent convulsive seizures, which pose the greatest 
risk, can be initiated whatever the epilepsy syndrome. Although EEG 
is used in prognostication for purposes of licensing by the Driver and 
Vehicle Licensing Agency, it is not essential for clinical management. 
Chronic epilepsy
While it may be appropriate for services to focus on the risk 
posed to those with first seizures, epilepsy is a prevalent condition 
and many thousands of patients have been disconnected from 
their usual neurology services for ongoing care. Telemedicine is 
entirely appropriate for the vast majority of outpatient epilepsy 
consultations. The challenge is to identify those in greatest need 
of contact who can then be prioritised, while ensuring that PWE 
know when and who to call to ask for help. Clinical coding may help 
identify those in greatest need to offer telephone appointments, 
such as those with complex epilepsy and learning disabilities. 
Letters should be sent to patients and carers, reminding them 
about the availability of telephone advice lines, reassuring and 
empowering them to seek help when needed from specialist 
services. Empowering patients in this way could lead to successful 
implementation of an ‘open access’ model of care for epilepsy, 
which improves patient outcomes.10 Increases in capacity 
of epilepsy specialist nurse telephone advice lines should be 
considered to meet the increased frequency of calls. 
Data from China indicate that the mental health of PWE has 
deteriorated during the pandemic, the negative psychological 
impacts being more pronounced in those with drug-resistant 
epilepsy.11 These individuals may need greater psychological 
support and access to practical self-help coping strategies, 
which may be available via charities and the voluntary sector 
organisations.12 Patients with vagal nerve stimulators in situ may 
also face additional challenges. Changes to programming should 
be deferred and urgent replacement of batteries should only 
be considered in those experiencing an increase in generalised 
seizures.13
Supporting epilepsy care in the ED and medical 
assessment unit
While the majority of patients with seizures in the community 
do not require hospital assessment and admission, patients 
with prolonged uncontrolled seizures or in status epilepticus 
should be assessed and treated urgently. Given that acute 
medical services are experiencing a sharp increase in workload 
during the COVID-19 pandemic, it is imperative that specialist 
neurologist input is readily available in EDs to advise on the 
appropriate management of seizures and other acute neurological 
presentations. Additionally, emergency care plans with clear 
thresholds to attend hospital should be considered for all PWE, 
with prescriptions for rescue medications issued for those most at 
risk. People with combined epilepsy and learning disability may be 
at highest risk, given that this vulnerable group of PWE commonly 
have refractory epilepsy, frequent seizures and/or communication 
difficulties, and may not have reliable alternative avenues to 
access specialist services.14
Ensuring continued anti-epileptic medication supply
Another concern is continuity of anti-epileptic drug (AED) supply 
for patients and ensuring that supply chains continue to function. 
At the time of writing, there appear to be no AED shortages as a 
direct or indirect result of COVID-19.15 Despite this, governments 
will have to ensure that they liaise with pharmaceutical regulatory 
bodies and industry partners to continually monitor the evolving 
impact of the COVID-19 pandemic on the supply chain and put 
in place measures to safeguard the availability of these essential 
medications. Perhaps a more pressing concern is ensuring that 
patients who are either self-isolating or have a disability continue 
to receive timely delivery of their AEDs to their place of residence. 
Pharmacy delivery services are likely to be overwhelmed due to 
an increase in demand and a decrease in staffing due to illness or 
isolation, which could lead to the possibility of delayed deliveries 
and missed AED doses as a result. A potential solution is prescribing 
adequate quantities of medication to patients, reducing the need 
for frequent repeat prescriptions; this must be carefully balanced 
with measures to prevent stockpiling. Another consideration will 
be the timely initiation and supply of AED therapy in patients with 
a new diagnosis of epilepsy. As more new diagnoses are made 
remotely, protocols will need to be in place to ensure the rapid 
and convenient distribution of new prescriptions to patients. This 
will require collaborative working between neurology and primary 
care, and utilisation of the digital prescribing infrastructure already 
available in community pharmacies.
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Conclusion
We must be proactive in implementing these crucial changes to 
our practice in this challenging time, as we have a duty to offer 
flexible and innovative clinical care during this pandemic to 
benefit our patients living with epilepsy and other chronic diseases. 
Despite initial timely cancellation of outpatient activity to enable 
redeployment and retraining, there has clearly been a delay in 
entering the next phase of robust contingency planning for routine 
clinical care and implementation of acute care plans. The revolution 
in our clinical practice should not yet come to an end, as it is clear 
that sustained change will be required to cope with the inevitable 
demand from subsequent phases of the disease, as well as the 
clinical backlog that will have resulted from the disruption caused by 
COVID-19. Core epilepsy services that have been paused indefinitely 
during the pandemic, including epilepsy surgery programmes and 
inpatient video telemetry, will need to be gradually reintroduced 
following re-triage of waiting lists. The legacy of COVID-19 
should be a reconfiguration of services that will persist beyond the 
pandemic, bringing improvements in efficiency and convenience, 
and a reduced environmental impact. In a time of undoubtedly 
increased anxiety for PWE, due to fears about supply of their critical 
medication or from the difficulties of isolation, it is important that 
they feel supported and know that, despite healthcare services 
being focused on combating the COVID-19 crisis, that they have 
not and will not be forgotten by their clinicians. 
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